150,000 Shares in Repligen Corporation $RGEN Bought by ABN Amro Investment Solutions

ABN Amro Investment Solutions bought a new stake in Repligen Corporation (NASDAQ:RGEN) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 150,000 shares of the biotechnology company’s stock, valued at approximately $151,000.

Other institutional investors and hedge funds have also modified their holdings of the company. TimesSquare Capital Management LLC lifted its holdings in shares of Repligen by 50.7% in the third quarter. TimesSquare Capital Management LLC now owns 362,129 shares of the biotechnology company’s stock worth $48,406,000 after acquiring an additional 121,898 shares during the last quarter. Aberdeen Group plc boosted its stake in shares of Repligen by 17.7% in the 3rd quarter. Aberdeen Group plc now owns 54,330 shares of the biotechnology company’s stock valued at $7,262,000 after purchasing an additional 8,152 shares during the last quarter. Johnson Investment Counsel Inc. grew its holdings in Repligen by 3.4% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 15,831 shares of the biotechnology company’s stock worth $2,116,000 after acquiring an additional 523 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in Repligen during the third quarter worth approximately $201,000. Finally, Portside Wealth Group LLC bought a new stake in shares of Repligen in the 3rd quarter valued at $294,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the company a “hold” rating in a report on Tuesday, October 28th. Barclays lifted their price target on Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Wells Fargo & Company boosted their target price on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Finally, Canaccord Genuity Group upped their price target on Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $177.92.

Insider Activity at Repligen

In other news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the sale, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. The trade was a 0.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.20% of the stock is owned by insiders.

Repligen Price Performance

Repligen stock opened at $135.41 on Wednesday. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $175.77. The company has a quick ratio of 7.14, a current ratio of 8.36 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.62 billion, a price-to-earnings ratio of 6,773.89, a PEG ratio of 2.49 and a beta of 1.13. The business has a 50-day simple moving average of $158.24 and a 200 day simple moving average of $146.09.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.